[Media Releases] [Health Korea News]Green Cross, sign of jackpot in the US. Publication: Health Korea News

Title: Health Korea News– Green Cross, signs of jackpot in the US. Publication: Health Korea News

Publication: Health Korea News / Ji Hye Kim

Date: 01 December 2011

Summary

• Green Cross reported the US FDA approved the clinical trial of new anticoagulant ‘GCC4401C”.

• ‘GCC4401C’ is a FactorXa Inhibitor blocks 10 major factors of thrombus to remove blood clots in vessels.

• In 2009, Green Cross bought a candidate substance for anticoagulant ‘GCC4401C’ from LegoChem Bioscience and in the same year, the state Ministry of Knowledge Economy selected the drug as a government funded bio-medical project.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).